Reference
Baglivo S, et al. Inflamed Tumor Phenotype as Predictor of Long-Term Response to Pembrolizumab in an EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) Patient with Acquired Resistance to Afatinib: a Case Report and Review of the Literature. Oncology and Therapy 10: 291-300, No. 1, Jun 2022. Available from: URL: http://www.springer.com/springer+healthcare/journal/40487
Rights and permissions
About this article
Cite this article
Afatinib/cisplatin/gemcitabine. Reactions Weekly 1962, 18 (2023). https://doi.org/10.1007/s40278-023-41688-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-023-41688-z